Plant Name: Helianthus annuus
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: |
|---|
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 1.997E-09 | 4.348E-05 | CYP1A2, CYP2C19, CYP2D6 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 5.341E-09 | 5.815E-05 | CYP19A1, CYP1A2, CYP2C19, CYP2D6 |
| BP | GO:0008152; metabolic process | GO:0006805; xenobiotic metabolic process | 2.351E-07 | 8.031E-04 | AHR, CYP1A2, CYP2C19, CYP2D6 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 1.760E-07 | 8.031E-04 | CYP19A1, CYP1A2, CYP2D6 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 3.746E-07 | 1.020E-03 | CYP19A1, CYP1A2, CYP2C19, CYP2D6 |
| MF | GO:0003824; catalytic activity | GO:0008395; steroid hydroxylase activity | 5.929E-07 | 1.291E-03 | CYP19A1, CYP2C19, CYP2D6 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 9.160E-07 | 1.662E-03 | CYP19A1, CYP1A2, CYP2C19, CYP2D6 |
| BP | GO:0008152; metabolic process | GO:0009820; alkaloid metabolic process | 5.059E-06 | 7.021E-03 | CYP1A2, CYP2D6 |
| BP | GO:0008152; metabolic process | GO:0008202; steroid metabolic process | 5.159E-06 | 7.021E-03 | CYP19A1, CYP1A2, CYP2C19, CYP2D6 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 2.682E-08 | 9.386E-07 | MAOA; CYP2D6; CYP1A2; CYP2C19 |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 1.994E-05 | 3.489E-04 | CYP2D6; MAOA; CYP2C19 |
| hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 1.737E-04 | 1.520E-03 | MAOA; CYP1A2 |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 9.070E-05 | 1.058E-03 | CYP1A2; CYP2C19 |
| hsa05030 | Cocaine addiction_Homo sapiens_hsa05030 | 2.613E-04 | 1.829E-03 | MAOA; DRD1 |
| hsa05031 | Amphetamine addiction_Homo sapiens_hsa05031 | 4.889E-04 | 2.445E-03 | MAOA; DRD1 |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 3.664E-04 | 2.138E-03 | CYP1A2; CYP19A1 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 5.802E-04 | 2.539E-03 | CYP2D6; CYP1A2 |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 2.276E-03 | 7.241E-03 | MAOA; CYP1A2; CYP2C19; CYP19A1 |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 7.315E-04 | 2.845E-03 | CYP1A2; CYP2C19 |
| hsa04728 | Dopaminergic synapse_Homo sapiens_hsa04728 | 1.796E-03 | 6.285E-03 | MAOA; DRD1 |
| hsa05034 | Alcoholism_Homo sapiens_hsa05034 | 3.419E-03 | 9.206E-03 | MAOA; DRD1 |
| hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 4.206E-03 | 1.051E-02 | DRD1; TSHR |
| hsa04080 | Neuroactive ligand-receptor interaction_Homo sapiens_hsa04080 | 7.993E-03 | 1.853E-02 | DRD1; TSHR |
| hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 2.473E-02 | 4.121E-02 | CYP19A1 |
| hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 2.766E-02 | 4.209E-02 | TSHR |
| hsa00330 | Arginine and proline metabolism_Homo sapiens_hsa00330 | 2.473E-02 | 4.121E-02 | MAOA |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 3.058E-02 | 4.459E-02 | CYP2C19 |
| hsa00350 | Tyrosine metabolism_Homo sapiens_hsa00350 | 1.737E-02 | 3.377E-02 | MAOA |
| hsa05320 | Autoimmune thyroid disease_Homo sapiens_hsa05320 | 2.619E-02 | 4.167E-02 | TSHR |
| hsa00260 | Glycine, serine and threonine metabolism_Homo sapiens_hsa00260 | 1.983E-02 | 3.652E-02 | MAOA |
| hsa04918 | Thyroid hormone synthesis_Homo sapiens_hsa04918 | 3.495E-02 | 4.704E-02 | TSHR |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 3.204E-02 | 4.485E-02 | CYP1A2 |
| hsa05412 | Arrhythmogenic right ventricular cardiomyopathy (ARVC)_Homo sapiens_hsa05412 | 3.640E-02 | 4.718E-02 | LMNA |
| hsa00340 | Histidine metabolism_Homo sapiens_hsa00340 | 1.194E-02 | 2.458E-02 | MAOA |
| hsa00360 | Phenylalanine metabolism_Homo sapiens_hsa00360 | 8.469E-03 | 1.853E-02 | MAOA |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 2.498E-03 | 7.285E-03 | CYP1A2 |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1 |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | MAOA |
| C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1 |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Dementia | F01-F07 | DRD1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | MAOA |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cocaine addiction | F14.2 | DRD1 |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | DRD1 |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | MAOA; DRD1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | DRD1 |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | MAOA |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychotic disorders | F20-F29 | DRD1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychiatric disorder | F01-F99 | DRD1 |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | MAOA |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | CYP2D6 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | MAOA |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | MAOA |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CYP2D6 |
| C00-D49: Neoplasms | Breast cancer | C50 | CYP19A1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | DRD1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | DRD1 |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | MAOA |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | CYP2D6 |
| C00-D49: Neoplasms | Bladder cancer | C67 | CYP19A1 |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Substance dependence | F10-F19 | DRD1 |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | MAOA; MAOA |
| NA: NA | HIV infections | NA | AHR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | MAOA |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | DRD1 |
| C00-D49: Neoplasms | Multiple myeloma | C90 | AHR |
| O00-O9A: Pregnancy, childbirth and the puerperium | Excessive bleeding following childbirth and spontaneous or elective abortion | O04 | DRD1 |
| N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1 |